Safety and efficacy of efalizumab in combination with methotrexate in patients with severe psoriasis: a comparative study.

niversity Medical Centre St. Radboud, Department of Dermatology0 个研究点目标入组 30 人开始时间: 2007年8月7日最近更新: 2021年10月8日

适应症

试验速览

暂无简介。

•1. Patients must be ³ 18 years of age.
•2. Patients must have a diagnosis of moderate to severe chronic plaque psoriasis.
•3. Patients must have a PASI ³ 10, or a PASI ³ 8 in combination with a Skindex-29 16 > 35.
•4. Patients must have failed to respond to phototherapy, methotrexate and/or cyclosporin in the past or have a contraindication for using phototherapy or cyclosporin.
•5. Patients must be free of any clinically significant disease (other than psoriasis) that would interfere with the study evaluations.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Patients who have non-plaque forms of psoriasis as the dominant form of psoriasis (e.g., erythrodermic, guttate or pustular).
•2. Patients who have current drug-induced psoriasis.
•3. Female patients who are pregnant, nursing and both men and women who are planning pregnancy during the study period or during the six months after receiving the last dose of study medication.
•4. Patients who have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, cerebral, or psychiatric disease.

发起方

niversity Medical Centre St. Radboud, Department of Dermatology